Technical Analysis for RARE - Ultragenyx Pharmaceutical Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
Crossed Above 200 DMA | Bullish | 0.00% | |
MACD Bullish Signal Line Cross | Bullish | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
Up 4 Days in a Row | Strength | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
NR7 | Range Contraction | 3.62% | |
Narrow Range Bar | Range Contraction | 3.62% |
Alert | Time |
---|---|
20 DMA Resistance | about 6 hours ago |
Rose Above 20 DMA | about 7 hours ago |
Up 1 ATR | about 7 hours ago |
Up 3% | about 8 hours ago |
Rose Above 200 DMA | about 8 hours ago |
Get a Trading Assistant
- Earnings date: 06/18/2024
Ultragenyx Pharmaceutical Inc. Description
Ultragenyx Pharmaceutical Inc., a development-stage biotechnology company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States. It develops various biologics product candidates, including KRN23, a human monoclonal antibody to bind and reduce the biological activity of fibroblast growth factor to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia; recombinant human beta-glucuronidase, an intravenous enzyme replacement therapy for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A, an enzyme replacement therapy for galactosialidosis. The company is also developing a range of small-molecule product candidates comprising triheptanoin, a substrate replacement therapy for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and oral formulation of sialic acid to treat hereditary inclusion body myopathy. It has license agreements with AAI Pharma Services Corp. and HIBM Research Group; and a collaboration and license agreement with Nobelpharma Co., Ltd. The company was founded in 2010 and is headquartered in Novato, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Acid Pharmacy Rare Diseases Monoclonal Antibody Phosphates Glucose Fatty Acids Fibroblast Growth Factor Myopathy Transporter Molecule Product Enzyme Replacement Therapy Mucopolysaccharidosis Biologics Deficiency Syndrome Pharma Services
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 54.98 |
52 Week Low | 31.52 |
Average Volume | 739,200 |
200-Day Moving Average | 42.06 |
50-Day Moving Average | 45.44 |
20-Day Moving Average | 42.68 |
10-Day Moving Average | 41.71 |
Average True Range | 1.70 |
RSI (14) | 45.95 |
ADX | 20.98 |
+DI | 19.42 |
-DI | 21.73 |
Chandelier Exit (Long, 3 ATRs) | 40.89 |
Chandelier Exit (Short, 3 ATRs) | 45.37 |
Upper Bollinger Bands | 45.19 |
Lower Bollinger Band | 40.18 |
Percent B (%b) | 0.49 |
BandWidth | 11.73 |
MACD Line | -1.23 |
MACD Signal Line | -1.29 |
MACD Histogram | 0.0624 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 45.39 | ||||
Resistance 3 (R3) | 45.21 | 44.10 | 44.92 | ||
Resistance 2 (R2) | 44.10 | 43.40 | 44.19 | 44.77 | |
Resistance 1 (R1) | 43.36 | 42.96 | 43.73 | 43.54 | 44.61 |
Pivot Point | 42.25 | 42.25 | 42.44 | 42.34 | 42.25 |
Support 1 (S1) | 41.51 | 41.55 | 41.88 | 41.69 | 40.61 |
Support 2 (S2) | 40.40 | 41.11 | 40.49 | 40.45 | |
Support 3 (S3) | 39.66 | 40.40 | 40.30 | ||
Support 4 (S4) | 39.84 |